Metabolomics and the great obstetrical syndromes--GDM, PET, and IUGR

Best Pract Res Clin Obstet Gynaecol. 2015 Feb;29(2):156-64. doi: 10.1016/j.bpobgyn.2014.04.023. Epub 2014 Aug 21.


Gestational diabetes mellitus, intrauterine growth restriction, and preeclamptic toxemia are common pregnancy complications that can have detrimental effects on morbidity and mortality of the mother and fetus as well as long-term health outcomes. Although they are distinct conditions, they may occur together and are often considered together as they share a common etiology of inadequate placental perfusion. The discovery and study of preventative treatments is hampered by a lack of effective screening tools to accurately identify women at the highest risk of disease. Metabolomics, an omic science, is the global quantitative assessment of endogenous metabolites within a biological system. It has proven to be a rapid approach in the identification of biomarkers predictive of the outcome of a pathological condition and the individual's response to a pharmacological treatment. We review the current and potential applications of metabolomics in maternal-fetal medicine, focusing on its use as a biomarker for great obstetrical syndromes diagnosis.

Keywords: GDM; IUGR; PET; metabolomics; newborn.

Publication types

  • Review

MeSH terms

  • Biomarkers / metabolism*
  • Diabetes, Gestational / diagnosis*
  • Diabetes, Gestational / etiology
  • Diabetes, Gestational / metabolism
  • Diabetes, Gestational / prevention & control
  • Female
  • Fetal Growth Retardation / diagnosis*
  • Fetal Growth Retardation / etiology
  • Fetal Growth Retardation / metabolism
  • Fetal Growth Retardation / prevention & control
  • Humans
  • Metabolomics*
  • Pre-Eclampsia / diagnosis*
  • Pre-Eclampsia / etiology
  • Pre-Eclampsia / metabolism
  • Pre-Eclampsia / prevention & control
  • Pregnancy
  • Prenatal Diagnosis*
  • Risk Factors
  • Syndrome


  • Biomarkers

Supplementary concepts

  • Preeclamptic toxemia